AnaptysBio, Inc. (NASDAQ:ANAB – Get Rating) has been given an average rating of “Hold” by the eight research firms that are presently covering the stock, MarketBeat reports. Four analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $34.00.
Several equities research analysts have recently commented on the company. Guggenheim boosted their price objective on AnaptysBio from $44.00 to $45.00 in a report on Friday, May 12th. StockNews.com began coverage on AnaptysBio in a report on Thursday, May 18th. They issued a “hold” rating on the stock. TD Cowen started coverage on AnaptysBio in a research report on Thursday, May 18th. They set an “outperform” rating on the stock. Finally, JPMorgan Chase & Co. upgraded AnaptysBio from an “underweight” rating to a “neutral” rating and dropped their price objective for the stock from $31.00 to $30.00 in a report on Monday.
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the business. Point72 Asset Management L.P. raised its stake in AnaptysBio by 196.6% in the 3rd quarter. Point72 Asset Management L.P. now owns 2,526,200 shares of the biotechnology company’s stock worth $64,443,000 after acquiring an additional 1,674,400 shares during the last quarter. Great Point Partners LLC increased its holdings in AnaptysBio by 5,262.2% in the 1st quarter. Great Point Partners LLC now owns 804,333 shares of the biotechnology company’s stock valued at $17,502,000 after purchasing an additional 789,333 shares during the last quarter. Braidwell LP acquired a new position in shares of AnaptysBio in the fourth quarter worth $22,503,000. Millennium Management LLC grew its stake in shares of AnaptysBio by 1,050.7% during the fourth quarter. Millennium Management LLC now owns 322,802 shares of the biotechnology company’s stock worth $10,004,000 after purchasing an additional 294,750 shares in the last quarter. Finally, State Street Corp lifted its position in AnaptysBio by 20.6% in the second quarter. State Street Corp now owns 1,155,881 shares of the biotechnology company’s stock valued at $23,464,000 after acquiring an additional 197,786 shares during the last quarter.
AnaptysBio Trading Down 1.5 %
AnaptysBio (NASDAQ:ANAB – Get Rating) last posted its earnings results on Thursday, May 11th. The biotechnology company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.04) by ($0.54). The firm had revenue of $1.37 million during the quarter, compared to the consensus estimate of $4.02 million. AnaptysBio had a negative net margin of 1,278.87% and a negative return on equity of 52.83%. As a group, analysts predict that AnaptysBio will post -6.42 earnings per share for the current fiscal year.
AnaptysBio Company Profile
AnaptysBio, Inc is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro.
- Get a free copy of the StockNews.com research report on AnaptysBio (ANAB)
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
- Best Buy’s Comeback Is Still At Play, Earnings Call For Patience
- e.l.f. Beauty Has Giant Quarter, Shares Hit New High
- If You Can Only Pick One Stock For The Rest Of 2023, Pick Nvidia
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.